Last reviewed · How we verify
NCT06667245
Impact on Quality of Life and Burden of Disease in Adults With Herpes Zoster
trial in Herpes Zoster in 357 participants. Not yet recruiting.
4 November 2025
Quick facts
| Lead sponsor | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 357 |
| Start date | 4 November 2024 |
| Primary completion | 4 November 2025 |
| Estimated completion | 4 November 2026 |
| Sites | 1 location across Spain |
Conditions studied
- Herpes Zoster — all drugs for Herpes Zoster →
- Quality of Life — all drugs for Quality of Life →
- Immunization; Infection — all drugs for Immunization; Infection →
Sponsor
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz — full company profile →
Who can join
18 and older, any sex, with Herpes Zoster or Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Title: Impact on quality of life and disease burden in adults with herpes zoster Prospective cohort study for the primary objective and the secondary objectives (1 and 2) and retrospective cohort study for the secondary objective 3. Disease or disorder under study: Patients with a herpes zoster (HZ) diagnosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06667245
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Herpes Zoster
Currently open trials in the same condition.
- NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine · Phase 1, PHASE2 · recruiting
- NCT07307170 — The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster · NA · recruiting
- NCT07293065 — A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) · Phase 3 · active not recruiting
- NCT07361796 — The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes · NA · recruiting
- NCT07378046 — The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster · NA · recruiting
Other Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz trials
Trials by the same sponsor.
- NCT07416760 — Analysis of the Composition of the Intestinal Microbiota in Patients Post-intestinal Anastomosis · recruiting
- NCT07115680 — Where Did the Authors Work When They Conducted Their Clinical Pharmacology Studies? · completed
- NCT07003308 — Anterior Versus Posterior White Line Advancement Technique in the Correction of Aponeurotic Ptosis · NA · recruiting
- NCT06968000 — Double-blind Pilot Study on the Effect of Anionic Exposome Enrichment (Biow) on Recovery and Sleep Quality in Postoperat · Phase 1, PHASE2 · recruiting
- NCT06163807 — Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06667245 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Last refreshed: 31 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06667245.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing